10 01, 2017

Illumina NovaSeq and other news

By | January 10th, 2017|Categories: Uncategorized|0 Comments

I’m not in tomorrow as I’m off to a funeral so I’ll not be writing anymore about the new sequencer from Illumina till later in the week. But here’s my initial thoughts… Illumina’s presentation at JP Morgan is over and they’ve certainly delivered. NovaSeq is the latest […]

5 01, 2017

My predictions for Illumina’s JP Morgan announcments

By | January 5th, 2017|Categories: Next-generation sequencing, Other stuff|4 Comments

I thought I’d follow Keith’s lead and make my own suggestions for what might be revealed during Illumina’s presentation at this years JPMorgan event. All the great announcements, by Illumina and everyone else, used to be made at the AGBT meeting in February and that gave […]

21 12, 2016

Problems for breast cancer researchers in 2017?

By | December 21st, 2016|Categories: "Experimental design controls etc", Other stuff|1 Comment

Breast cancer researchers publish a lot of papers, and a large number of those will include some genomics, variant identification, RNA-Seq, ChIP-Seq, etc. Increasingly research is being carried out on patient derived material, but cell lines are still a vital part of much of the […]

15 12, 2016

The 5 hardest things about single-cell sequencing

By | December 15th, 2016|Categories: Next-generation sequencing, Single-cell sequencing|2 Comments

Single-cell sequencing is making waves with many exciting developments over the last couple of years. Hardware is available from the companies like 10X Genomics, Fluidigm, Wafergen, BioRad (see GenomeWeb), RainDance (see GenomeWeb), Dolomite Bio. Chemistry for RNA and Genome sequencing such as SMART-Seq V4 and TruPrime, opens up all sorts […]

13 12, 2016

Oxford Nanopore – a billion dollar valuation!

By | December 13th, 2016|Categories: Next-generation sequencing|0 Comments

The latest round of fundraising by ONT brought in over $100 million, that makes a total of around $X million invested over the last X years. This round of funding was led by GT Healthcare, a Hong Kong based investment group. According to the Financial Times […]

11 12, 2016

The new sequencer from Qiagen

By | December 11th, 2016|Categories: Next-generation sequencing|0 Comments

Qiagen are now finally selling the GeneReader after a hiatus of several years. This was caused by issues getting a working instrument out of the original IBS technology, and also held, temporarily, up by recent Illumina litigation. GenomeWeb covered the relaunch back in November. Qiagens updated […]

Load More Posts